You are here

Self-administered pension schemes (SAPS) FAQs

A brief history of the self-administered pension scheme (SAPS) mortality investigation?

Historically pension schemes in the UK have used mortality tables based on population data or data collected from insurance companies. In 1997 the Pensions Board of the Institute and Faculty of Actuaries and the CMI began considering the feasibility of research into the mortality experience of UK self-administered pension schemes. It was decided that a pilot investigation would be run on a small subset of self-administered schemes to see how the mortality compared to that of insured pensioners.

The results of this investigation were published in CMI Report 20 in 2001 and concluded amongst other things that the experience investigated was different from that underlying the insured pensioner investigation.

In 2002 further discussions were held and a decision to begin a more wide-ranging and substantial investigation into the mortality of self-administered schemes was taken. Initially a Working Party was formed and this subsequently became an official committee of the CMI in July 2006.

What data should be submitted?

Data should only be submitted for current pensioners, that is data in respect of retired members or pensions paid to dependants. Data should not be submitted in respect of deferred and active members of the pension scheme. Normally, data will be submitted by the Scheme Actuary responsible for the scheme.

At this stage only large schemes, those with more than 500 pensioners, are requested. This number was based on an analysis of the expected number of schemes and the cost of the whole investigation. Including smaller schemes would add to the cost without adding significantly to the validity of the data collected.

When should data be submitted?

Data can be submitted at any time but we expect that in most cases data submissions are made soon after the scheme valuation, with data from the valuation. This will usually be every three years, although schemes having annual valuations can submit each years data separately.

In what format should data be submitted?

The coding guide contains all the information required. Find out more about data submissions and for access to the latest coding guide. If you have any queries about data submission, please contact us on 020 7776 3820 or email self-admin@cmilimited.co.uk.

How are data problems handled by the CMI?

To keep the costs of the investigation down, the data must be provided in the standard form shown in the data specification. The CMI makes a limited number of checks on the data. If an error condition on a record can be corrected in some predetermined way (e.g. a missing amount of pension at the date of death) the system automatically updates the record (although in these cases it is preferable for the submitting firm to estimate these). If this cannot be done then the record is rejected.

The analysis is then performed on those records not rejected. In addition to the individual results report that is sent to the consultancy that supplied the data, a report that includes a brief summary of data that has been analysed, e.g. the number of records and the number of deaths, and details of records that have been rejected or amended is also provided.

The CMI performs limited checks on the results in respect of each scheme but asks that those submitting the data confirm that the results and supplementary report are consistent with what they expect, or otherwise to advise the CMI that this is not the case. Data should be resubmitted if the latter is true.

For the aggregate analyses, a scheme is removed if the number of the records that are rejected exceeds a predetermined threshold or if the data supplier advises the CMI that the data is inaccurate.

What results are produced from the investigation?

Two types of results are produced.

  • Individual scheme results comparing actual deaths with the deaths expected according to certain base tables are reported to the consultancy who supplied the data. Comparisons for males and females, by lives and amounts, and for different pensioner types are produced.
     
  • Aggregate results, analysing data for multiple schemes, are also produced based on scheme data submitted by 30 June each year. Additional analyses such as mortality trends and mortality by industry class are also planned. Aggregate results are normally published initially in draft form to members of the SAPS mortality investigation and in final form within working papers six months later.

Results show Actual experience versus Expected. How is Expected calculated?

The expected experience is calculated by applying the central exposure at each age with a base table of mortality. There are two bases currently used for these comparisons. The first basis is a table from the S1 series of mortality tables where the actual table depends on the pensioner type. The second basis is the 00 series normal retirement, based on the 1999-2002 investigation of insured lives.

Where can I find results?

Aggregate scheme results have been published in a series of working papers to date, with the most recent being Working paper 31. Please click here to access these papers. Additionally, documentation of the investigation's methodology and assumptions can be found in Working paper 34.

Has the SAPS investigation produced any mortality tables?

The SAPS experience for the period 2000-2006 has been graduated to produce the S1 series of mortality tables, the first mortality tables to be based on UK pension scheme data. These were published in October 2008 and have been formally adopted by the Institute and Faculty of Actuaries. The S1 tables along with all graduations methodology can be found in Working paper 35.

Contact Details

If you have any questions about the CMI please email

info@cmilimited.co.uk

Filter or search events

Start date
E.g., 15/07/2020
End date
E.g., 15/07/2020

Events calendar

  • Current Issues in Life Assurance (CILA) Webinar series

    Webinar Series
    15 July 2020 - 3 August 2020

    Spaces available

    CILA is one of the pre-eminent events in the annual 'Life' calendar. Due to COVID-19 we are running the programme as a series of webinars covering topics aimed at practicing life actuaries from life offices, consulting firms and other employers of actuaries and those who work in or advise on, the life assurance market in the UK and Europe.

  • Spaces available

    Current Issues in Life Assurance - For annuity writers, a key challenge is the need to fund capital-consumptive new business strain (NBS) as a consequence of writing the business intended to fund future distributions. Reinsurance, investment strategy and capital provision all have roles to play which we will investigate in this webinar

  • Spaces available

    Current Issues in Life Assurance – Mortality in 2020 is now dominated by one thing, although – in our future-focused world – the pandemic is just one of many mortality considerations.  In this session, three well-regarded mortality/longevity specialists provide an overview of implications and impacts of COVID-19, recent and imminent CMI developments and more 'future focused' work in the MRSC

  • Spaces available

    Because of Covid-19, forecasters predict a severe recession in 2020, followed by a V or U-shaped recovery. This impacts both individuals and companies. However, compared to previous recessions, the impact on banks of higher credit losses should be mitigated to some extent by government actions. 

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series

    This session will provide an overview of the Population Health Management Working Party's research including defining impactability and impactability modelling, discussing some examples of specific modelling approaches, considering the practical challenges across the NHS as well as wider public perception and ethical issues.

  • Spaces available

    Many actuaries consider career opportunities in the Finance and Investment practice area after having started off in more traditional actuarial roles such as valuations, capital management or pricing. This session is aimed at helping actuaries to better understand roles in Finance and Investment and how they can fine tune their skills to pursue such careers.

  • Mortality and Longevity Webinar Series 2020

    Webinar Series
    22 July 2020 - 10 August 2020

    Spaces available

    Due to COVID-19, we are running this programme via a series of webinars commencing 22nd July.

    This webinar series will provide topical and practical updates and discussion on the latest thinking and innovations in mortality and longevity, and is designed to be very accessible to a broad range of experience.

     

  • Spaces available

    Insurers are making increasing use of medical research to help with assumption, models and underwriting. Experienced mortality/ longevity specialists discuss the issues in the interpretation of  medical research papers, using a range of case studies. The case studies will include COVID-19 points of current importance. Many of the concepts discussed (data bias, inference of causation) are also applicable to equivalent questions in 'big data' and advanced analytics.

  • Spaces available

    Members of the Mortality Working Group of the IAA have analysed changes in mortality for about 30 causes of death  and will discuss how causes of death are classified, and the problems of long-term data, appropriate metrics, including "years of life lost" (YLL), causes of death - a "measure of cohortness", the changes in dominant causes of death at older ages, and how can these types of studies enhance mortality forecasting.

  • Spaces available

    Predictive risk assessment and risk stratification models based on postcode-level consumer classification are widely used for life insurance underwriting. However, these are socio-economic models not directly related to health information. Similar to precision medicine, precision life insurance should aim to tailor policy pricing/reserving to the individual health characteristics of each client.

  • Spaces available

    This discussion, the fourth in the Extreme Mortality Events webinar series, will look at what poor model selection and calibration could look like – using inappropriate historical data; using incorrect 2020 mortality data; and inappropriate stochastic model recalibration (or lack thereof). Presented by Chair of the Life Board of the Institute and Faculty of Actuaries, Colin Dutkiewicz. 

  • Spaces available

    This webinar has been re-scheduled from its original date of the 1st July. Although ESG has many buyers across the asset allocation community, from pension funds to sovereign wealth funds, it still hasn’t found its place within the core asset management strategy desks where the money is actually invested. The problem as well as the opportunity is Fixed Income. Plenty of strategies exist for incorporating ESG within Equities, from screening, integration to a combination. ESG has picked up relatively quickly within Equities with rating,indices created using ESG factors. This talk will discuss how we price a quantifiable ESG credit risk premium and make it alpha worthy in a strategy. 

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series

    With the rising prevalence of dementia, how can we manage this risk effectively and can insurance do more? Matt Singleton, Ageing Lead at Swiss Re, will cover these topics and demonstrate how insurance could help people address their concerns.

  • Spaces available

    Current Issues in Life Assurance – Join us for an exploration session on the use of data science in insurance companies today including how insurers are making sense of and using new data sources and technologies, exploration of practical applications of data science within actuarial work, benefits of data-driven decisions to solve business problems using the power of data and technology, and the role that actuaries can play to harness the benefits of data science.

     

  • Spaces available

    Current Issues in Life Assurance

    This talk will look at a range of such techniques (e.g. mass lapse risk transfer, contract boundaries, risk margin relief, non-standard longevity risk transfer) that have been applied or considered by UK and EU insurers, and the pros and cons of each.

     

  • Spaces available

    Current Issues in Life Assurance.

    The International Association of Insurance Supervisors announced on 14 November 2019 the adoption of v2.0 of the global Insurance Capital Standard (ICS) which will undergo confidential reporting for 5 years starting from 2020. This session will include specific experiences from Legal and General (L&G) as well as global industry perspectives from EY.

  • Spaces available

    Current Issues in Life Assurance

    This session will cover the PRA supervisory statement on financial impacts related to climate change, industry insights into PRA climate risk business plans, examples climate risk strategy setting out key workstreams and activity steps for successful execution, an overview of a climate risk strategy execution timeline and the future.     

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series. Using new and unique research and data from the UK, US, Sweden and China, this presentation investigates how consumers use the internet through their insurance journey and analyzes the role culture and generation plays in their online behaviour. We use this research to show the online landscape for insurance sales in the UK and suggest ways to shape new products and effectively engage with the consumer who is buying them.

  • Spaces available

    Chief Medical Officer (CMO) for Gen Re Life/Health Research and Development, Dr John O'Brien, will discuss the impacts of Gene Modification for life/health insurance. 

  • Spaces available

    As an industry, it has been important to be able to look to the future to identify the next quantifiable risk. In this session, I will explore some of the less tangible, but none-the-less concerning risks to future health, such as the health risks associated with exposure to pesticides, ingestion of plastic in the food chain, and the hazards of indoor air pollution through exposure to volatile organic compounds.

  • Spaces available

    The working party will help the industry to update and enhance how potential risk from diabetes and excess mortality is considered, including the need to understand the underwriting implications as treatments improve, and potentially to develop new products that are tailored to those with diabetes.

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series. Modelling the structure and trends of cancer morbidity risk is important for pricing and reserving in related health insurance fields such as critical illness insurance and care provision. We model the dynamics of cancer incidence over time in different regions in England, using 1981-2016 ONS data. The modelling allows estimation of cancer rates at various age, year, gender and region levels, following a Bayesian setting to account for statistical uncertainty. Our analysis indicates significant regional variation in cancer incidence rates. 

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series. In this talk we will outline the steps Aviva took in pulling together our first large-scale disclosures on the exposure of our business to climate change published in March 2019; in line with the recommendations of the Taskforce on Climate-related Financial Disclosures. After touching on why insurers have such an important role in climate change, we'll cover a brief “how-to” guide for those who have not yet embarked on thinking about these topics before giving a case study of how the learnings from a TCFD disclosure exercise can be applied to investment portfolios.

  • Spaces available

    Part of the Protection, Health and Care Conference 2020 webinar series. 

    The insurance industry currently underwrites customers with diabetes based on a range of factors, medical expertise and various medical studies. The work undertaken by the Diabetes Working Party would help the industry to approach this using current research findings to update and enhance how potential risk from diabetes is considered. This includes the need to understand the underwriting implications as treatments improve, and potentially to develop new products that are tailored to those with diabetes. This webinar will present our latest findings in the management of this important chronic condition which will include research in collaboration with the ARC.